NovoCure (NVCR) Debt to Equity (2015 - 2026)

NovoCure has disclosed Debt to Equity across 12 years of filings, most recently posting $0.59 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.59, up 119.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.59 (up 119.52% YoY), and the FY2025 annual result was $0.57, up 112.07% from the prior year.
• Debt to Equity came in at $0.59 for Q1 2026 at NovoCure, up from $0.57 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $1.59 in Q1 2024 to a low of $0.27 in Q2 2024.
• The 5-year median for Debt to Equity is $0.93 (2022), against an average of $0.87.
• Across the five-year window, Debt to Equity tumbled 83.02% in 2025 and soared 119.52% in 2026, its largest moves.
• NovoCure's Debt to Equity stood at $1.28 in 2022, then climbed by 12.55% to $1.44 in 2023, then tumbled by 81.27% to $0.27 in 2024, then soared by 112.07% to $0.57 in 2025, then grew by 3.17% to $0.59 in 2026.
• The last three Debt to Equity figures came in at $0.59 (Q1 2026), $0.57 (Q4 2025), and $0.57 (Q3 2025), per Business Quant data.